DEBOXA for Inoperable NET Liver Metastases

Inclusion Criteria: * Diagnosis is confirmed by biopsy or clinical data, primary site is resected or primary site is not resected but without risks of bleeding, obstruction in the near future. * Failure of ≥ 1 system treatment, such as long-acting somatostatin or EP chemotherapy regimen. * Standard surgical resection can not be performed because of extent liver involvement （liver involvement ≥ 2 lobes or ≥ 2 major vessels）, or patients who are not willing to accept surgical operation. * Predicted survival \>3 months. * Child Pugh Score: ≤ 7 * ECOG score for performance status: 0-1 * Informed consensus is achieved. Exclusion Criteria: * Metastases to other organs or sites besides liver. * Prior TACE for liver tumors in 1 year. * Obvious hepatic arterio-venous shunt or arterio-portal shunt. * Prior or concurrent malignancy (Except basal carcinoma or squamous carcinoma of skin or carcinoma in situ of cervex uteri which has been cured). * Platelet count \< 50,000/mm\^3 or white blood cell count \<3,000 /mm\^3 without hypersplenism. * Creatinine greater than upper limit of normal (ULN) * AST or AST \> 5 times ULN * Compromised coagulation: INR (International normalised ratio) \>1.5, current anti-coagulation therapy or hemorrhagic disorders. * History of severe diseases involving heart, kidney, marrow, lung or central neural system. * Infection diseases which need antibiotics treatment before less than 1 month. * Co-existing morbidity or social environment which may lead patients not to obey study protocol or threat patients' safety.